Life Sciences

  • March 02, 2026

    Amazon Can't Halt Supplement Labeling Suit Amid FDA Tweak

    A Washington federal judge denied Amazon's bid to pause a proposed class action over claims of deceptive supplement labeling based on the U.S. Food and Drug Administration's purported plan to revoke certain regulations, finding Friday the court or a jury can still address whether the e-commerce platform complied with existing requirements.

  • March 02, 2026

    Hagens Berman Denied Rehearing Bid In Sanctions Dispute

    The Third Circuit on Monday rejected plaintiff's firm Hagens Berman Sobol Shapiro LLP's request to reconsider weighing in on the sanctions dispute in a since-dropped product liability case that resulted in the trial court judge referring the firm for possible criminal investigation.

  • March 02, 2026

    Gyre, Cullgen Merge in $300M All-Stock Deal

    Commercial-stage biopharmaceutical company Gyre Therapeutics Inc. on Monday announced plans to acquire clinical-stage biopharmaceutical company Cullgen Inc. in an all-stock deal valued at roughly $300 million.

  • March 02, 2026

    J&J Unit Wins Bid To Revive Talc Libel Suit With New Basis

    A New Jersey federal judge has revived a bankrupt Johnson & Johnson talc subsidiary's trade libel claim over a 2020 scientific article linking asbestos in talc to mesothelioma, finding that new evidence and allegations concerning the authenticity of the author's data are enough to survive a motion to dismiss.

  • March 02, 2026

    Drugmakers Warn Justices Oregon Pricing Law Risks Secrets

    Pharmaceutical manufacturers have asked the U.S. Supreme Court to overturn Oregon's drug‑pricing transparency law, arguing it forces companies to publicly justify their pricing decisions and give up valuable trade secrets in violation of the First Amendment and the Constitution's takings clause.

  • February 27, 2026

    PetMed, Elanco, Tractor Supply Settle Flea & Tick Med Claims

    PetMed Express, Tractor Supply Co. and Elanco Animal Health are the latest to settle with consumers in a case accusing Elanco of paying pet supply retailers not to stock generic versions of its Advantix topical flea and tick prevention drug, according to several orders filed in Indiana federal court.

  • February 27, 2026

    Fed. Circ. Urged To Undo Attys' DQ In Patent Fight

    Two men listed as inventors on allergy test patents asked the Federal Circuit to vacate an order that disqualified attorneys who had represented the pair for almost four years in a case from a Maine physician who claimed he should be the sole inventor.

  • February 27, 2026

    AI-Focused Generate Biomedicines Prices $400M IPO

    The CEO of Generate Biomedicines, a biotechnology firm using artificial intelligence to develop therapies for immunology and oncology, on Friday rang the Nasdaq opening bell as the company expects to raise $400 million for its initial public offering.

  • February 27, 2026

    Bristol-Myers Campus Sale Suit Sent Back To NJ

    A dispute over the sale of a 433-acre Bristol-Myers Squibb Co. research campus was sent back to state court after a New Jersey federal judge held that the addition of a "diversity-destroying" plaintiff was not out of bounds.

  • February 27, 2026

    3rd Circ. Preview: Janssen, Penn State Prof. Seek Relief

    A packed March argument calendar will put several high‑stakes disputes before the Third Circuit, including a billion‑dollar False Claims Act judgment and challenges at the intersection of academic freedom, DEI programming, cannabis‑sector finance and campus Title IX procedures.

  • February 27, 2026

    Credit Bureaus Fight Bid To Add Plaintiffs, Claims To Suit

    Medical providers and a collection agency in a proposed class action accusing Equifax, Experian and TransUnion of conspiring to exclude less than $500 in medical debt from consumer credit reports lack good cause to again amend their complaint, the credit reporting agencies told a federal court. 

  • February 27, 2026

    Mastectomy Bras Found Not Distinct Enough To Be Duty-Free

    Imported brassieres specifically designed for those who have undergone a mastectomy aren't so specialized as to qualify as duty-free prostheses accessories, the U.S. Court of International Trade ruled Friday, saying they are properly categorized alongside standard brassieres.

  • February 27, 2026

    Life Sciences Group Of The Year: Goodwin

    Goodwin Procter LLP advised Blueprint Medicines in its $9.5 billion acquisition by Sanofi and represented SpringWorks Therapeutics as it was purchased by Merck for $3.9 billion, earning the firm a spot among the 2025 Law360 Life Sciences Groups of the Year.

  • February 27, 2026

    Minn. State Sens. Introduce Medical Psilocybin Bill

    A pair of Minnesota state senators have introduced a bill to create and regulate a medical psilocybin use program, which would allow residents over 21 with qualifying medical conditions to cultivate and use the drug to treat their conditions.

  • February 27, 2026

    Taxation With Representation: Linklaters, Wilson Sonsini

    In this week's Taxation With Representation, French electric utility Engie acquires UK Power Networks, Gilead Sciences Inc. buys clinical-stage biotechnology company Arcellx Inc., and The Brink's Co. acquires NCR Atleos in a deal that unites two major companies in the ATM business.

  • February 27, 2026

    121-Year-Old Ruling Still A Shot In The Arm For Vax Mandates

    Having already withstood five global pandemics, 21 presidencies and more than a century of developments in both the law and public health policy, the U.S. Supreme Court's most durable precedent blessing mandatory vaccination is well positioned to survive a new wave of challenges, experts say.

  • February 26, 2026

    IRhythm Investors Say 2021 Goldman Ruling Doesn't Bar Cert.

    IRhythm Technologies investors urged a California federal judge Thursday to certify a class that bought 30 million shares while the digital healthcare company allegedly jacked its stock price with false and misleading statements about a heart-event monitoring device, saying the U.S. Supreme Court's 2021 Goldman price impact ruling doesn't apply.

  • February 26, 2026

    Health Plans Lack Expert In Avandia MDL, 3rd Circ. Told

    Counsel for GlaxoSmithKline urged a Third Circuit panel on Thursday to undo an order certifying a class of health plans in the multidistrict litigation over the company's alleged deceptive marketing of the diabetes drug Avandia, arguing the plaintiffs didn't have the experts necessary to support their case.

  • February 26, 2026

    Justices Told 'Skinny Label' Case Puts Generic Drugs At Risk

    The U.S. government, one named sponsor of the Hatch-Waxman Act, a generic-drug industry group and more have warned the U.S. Supreme Court that a decision that allowed a patent case involving a so-called skinny label to proceed threatens the availability of low-cost generic drugs.

  • February 26, 2026

    Squires Grants 3 IPRs, Denies 10, Marks RPI Order Informative

    U.S. Patent and Trademark Office Director John Squires has issued guidance on when real-parties-in-interest errors won't lead to denied petitions, and then instituted three inter partes reviews in his latest bare-bones mass decision.

  • February 26, 2026

    Chancery Asked To OK $7.6M Deal To End $1.5B De-SPAC Row

    Stockholders of special purpose acquisition company HighCape Capital LP have sought Delaware Court of Chancery approval for a $7.6 million settlement of a class suit accusing company principals of pursuing an overpriced take-public merger of biopharmaceutical tech company Quantum-Si, in litigation complicated by an unusual discovery stumble.

  • February 26, 2026

    Boston Scientific Wins Toss Of Spinal Device Suit

    Boston Scientific escaped a suit alleging that its spinal implant device malfunctioned and caused a Michigan man pain and permanent injuries, after a federal judge ruled that each of the plaintiff's claims are preempted by federal law.

  • February 26, 2026

    Kenvue Can't Duck Texas AG's Tylenol Autism Suit

    A Texas state court Thursday rejected Kenvue's bid to toss a lawsuit that Texas' attorney general has brought alleging Tylenol taken during pregnancy could cause autism in children, even though it is marketed as the safest pain relief for pregnant women and young children.

  • February 26, 2026

    $200M Antitrust Deal Can Shield Drugmakers In States' Claims

    Sun Pharmaceutical and Taro Pharmaceuticals can use their $200 million settlement with the "end payors" for generic drugs in an alleged price-fixing scheme as a defense in a similar lawsuit brought by 47 states and territories, the Connecticut federal judge overseeing the case ruled Wednesday.

  • February 26, 2026

    Life Sciences Group Of The Year: Covington

    Covington & Burling LLP's recent work advising Novartis on its $12 billion acquisition of Avidity Biosciences Inc., boosting the Swiss pharmaceutical giant's neuroscience portfolio, is among the reasons the firm landed among the 2025 Law360 Life Sciences Groups of the Year.

Expert Analysis

  • FDA's Biosimilarity Guidance Holds Uncertain Implications

    Author Photo

    The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.

  • Unpacking Key Themes From NY's New Healthcare Strategy

    Author Photo

    New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.

  • 5 Different AI Systems Raise Distinct Privilege Issues

    Author Photo

    A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.

  • Opinion

    AI-Assisted Arbitration Needs Safeguards To Ensure Fairness

    Author Photo

    As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, ​​​​​​​clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.

  • Trans Care Enforcement Landscape Is Evolving Quickly

    Author Photo

    The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.

  • Series

    Playing Piano Makes Me A Better Lawyer

    Author Photo

    Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.

  • 3 Cases Highlight SEC Distinction Between Exec, Co. Liability

    Author Photo

    Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.

  • AI-Generated Doc Ruling Guides Attys On Privilege Risks

    Author Photo

    A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.

  • The Law Firm Merger Diaries: Leadership Strategy After Day 1

    Author Photo

    For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here